ENGN vs ENVB

enGene Therapeutics Inc. vs Enveric Biosciences, Inc. — Valuation Comparison 2026

ENGN

Biotechnology
enGene Therapeutics Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.78
Last close
Models
8/13
Active
VS

ENVB

Biotechnology
Enveric Biosciences, Inc.
Quality
3.8
out of 10
Value Trap
39
LOW
Price
$2.32
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ENGN Fair ValueENGN Upside ENVB Fair ValueENVB Upside
Bayesian DCF Intrinsic $0.58 -67.6% $1.35 -41.8%
Earnings Power Value Intrinsic $2.37 -40.5%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.92 +8.1% $2.37 +2.0%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENGN vs ENVB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENGN vs ENVB — Which Stock Is More Undervalued?

ENGN scores higher with a 4.1/10 quality rating vs ENVB's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing enGene Therapeutics Inc. (ENGN) and Enveric Biosciences, Inc. (ENVB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENGN currently trades at $1.78 with a QOC of 4.1/10, while ENVB trades at $2.32 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).